Reardon Andrew sold $1.6M of LGND
Reardon Andrew (CLO & Secretary) sold 5,000 shares of LIGAND PHARMACEUTICALS INC (LGND) at an average of $313.28 ($308.99–$317.15, $1.57M total) across 8 trades on 2026-07-01 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest fact is the disclosed open-market sale amount and execution details; it can influence short-term sentiment but is not a fundamental catalyst on its own.
Market read
Traders may monitor insider activity, but the 10b5-1 framing suggests limited incremental information for valuation.
What to watch
The article does not state whether other insiders sold/bought, nor does it provide context on total insider holdings changes beyond the post-transaction share count.
Background
The article is an SEC Form 4 insider transaction disclosure for Ligand Pharmaceuticals (LGND).
Ticker impact
Ligand Pharmaceuticals insider Andrew Reardon (CLO & Secretary) sold about $1.57M of LGND shares via an open-market sale under a 10b5-1 plan.
Likely limited near-term impact; any move would be sentiment-driven and small unless paired with other news.
The filing is a Form 4 insider transaction with a stated pre-arranged 10b5-1 plan and no accompanying operational/regulatory/company-specific catalyst in the text.
Market effects
No sector read-through provided; this is company-specific insider dealing only.
None indicated.
None indicated.
Counterpoint
Because the sale is under a 10b5-1 plan, it may reflect scheduled liquidity rather than negative expectations; traders may discount it.
Key entities
- Equity issuerLGND
Ligand Pharmaceuticals Inc., the company whose insider sale is disclosed.
- InsiderAndrew Reardon
CLO & Secretary at Ligand Pharmaceuticals; executed the reported open-market sale.
